Deep knowledge on 
 small-molecule drugs and 
 the 100,000 global patents 
 covering them 

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

How are People Using DrugPatentWatch?

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: ELIQUIS

« Back to Dashboard
Eliquis is a drug marketed by Bristol Myers Squibb and is included in one NDA. It is available from two suppliers. There are two patents protecting this drug.

This drug has eigthy-eight patent family members in thirty-six countries.

The generic ingredient in ELIQUIS is apixaban. There are four drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the apixaban profile page.

Summary for Tradename: ELIQUIS

Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: see list8

Pharmacology for Tradename: ELIQUIS

Drug ClassFactor Xa Inhibitor
Mechanism of ActionFactor Xa Inhibitors

Clinical Trials for: ELIQUIS

Assessment of an Education and Guidance Programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN)
Status: Recruiting Condition: Non-valvular Atrial Fibrillation

Apixaban Evaluation of Interrupted Or Uninterrupted Anticoagulation for Ablation of Atrial Fibrillation
Status: Recruiting Condition: Atrial Fibrillation

Pharmacokinetics and Pharmacodynamics of Apixaban in Nephrotic Syndrome
Status: Recruiting Condition: Nephrotic Syndrome; Proteinuria

Bioavailability of Apixaban Crushed Tablet
Status: Completed Condition: Thrombosis

Apixaban Versus Dual-antiplatelet Therapy (Clopidogrel and Aspirin) in Acute Non-disabling Cerebrovascular Events
Status: Not yet recruiting Condition: Ischemic Stroke; TIA

A Study to Assess the Effects of 2 Prothrombin Complex Concentrates on the Pharmacodynamics of Apixaban in Healthy Adult Subjects
Status: Completed Condition: Anticoagulation

Early Post-marketing Study of Eliquis (Apixaban)
Status: Active, not recruiting Condition: Non-valvular Atrial Fibrillation (NVAF)

Phase 1 Oral Solution Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects
Status: Completed Condition: Healthy Volunteers

Phase 1 Oral Solution and Crushed Tablet Relative Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects
Status: Completed Condition: Healthy Subjects

Oral Apixaban (Eliquis) Versus Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic Malignancy
Status: Recruiting Condition: Gynecologic Cancer; Venous Thromboembolism

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol Myers Squibb
ELIQUIS
apixaban
TABLET;ORAL202155-001Dec 28, 2012RXNo6,413,980<disabled>YY <disabled>
Bristol Myers Squibb
ELIQUIS
apixaban
TABLET;ORAL202155-002Dec 28, 2012RXYes6,413,980<disabled>YY <disabled>
Bristol Myers Squibb
ELIQUIS
apixaban
TABLET;ORAL202155-002Dec 28, 2012RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ELIQUIS

Country Document Number Publication Date
Germany122011100050Mar 15, 2012
Israel203533Dec 29, 2011
European Patent Office2105436Sep 30, 2009
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc